Form 4 for CAI Caris Life Sciences, Inc.

Accepted 2025-06-23 00:00:00 ET · period of report 2025-02-27 · accession 0001104659-25-061813 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2025-06-23	2025-06-20	CAI	HALBERT JON	Dir	C - Cnv Deriv	$0.00	+1.25M	1.25M	New	$0
D	2025-06-23	2025-02-27	CAI	HALBERT JON	Dir	A - Grant	$0.00	+16.1K	116.1K	+16%	$0
DI	2025-06-23	2025-06-20	CAI	HALBERT JON	Dir	C - Cnv Deriv	—	-5.00M	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-06-20	C	A	1,250,000	$0.00	1,250,000	I	—	—
2	Common	Common Stock	2025-02-27	A	A	16,129	$0.00	116,129	D By Ke'Ohana Ventures, LLC	—	—	(F1) Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025. (F3) The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
3	Derivative	Series A Preferred Stock	2025-06-20	C	D	5,000,000	—	0	I By Ke'Ohana Ventures, LLC	$0.00 · — to —	1,250,000 Common Stock	(F2) Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock. (F3) The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.